Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of “Moderate Buy” from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $20.00.

A number of equities research analysts have recently commented on the stock. Wedbush cut shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and cut their price target for the company from $29.00 to $4.00 in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Stifel Nicolaus dropped their price objective on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Robert W. Baird lowered their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Finally, RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Alto Neuroscience Stock Performance

Shares of NYSE ANRO opened at $4.52 on Monday. The company has a current ratio of 13.10, a quick ratio of 19.85 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a 1 year low of $3.61 and a 1 year high of $24.00. The company’s 50-day moving average is $9.69 and its 200 day moving average is $11.30.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. On average, analysts anticipate that Alto Neuroscience will post -2.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its holdings in shares of Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Alto Neuroscience in the second quarter worth about $113,000. Jane Street Group LLC bought a new position in Alto Neuroscience during the third quarter valued at approximately $124,000. Federated Hermes Inc. grew its holdings in Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after buying an additional 3,000 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new stake in Alto Neuroscience in the 3rd quarter worth approximately $146,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.